Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice

Diabetologia

Volumn 57, Issue 6, 2014, Pages 1257-1267

  Plante, Eric ^a,b   Menaouar, Ahmed ^a   Danalache, Bogdan A ^a,b   Broderick, Tom L ^c   Jankowski, Marek ^a,b   Gutkowska, Jolanta ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Brain natriuretic peptide; Cardioprotection; Diabetes; Fibrosis; Insulin resistance; Obesity

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; FAT CONTENT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; OBESITY; OSMOTIC PUMP; PRIORITY JOURNAL; TOMOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; C57BL MOUSE; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; METABOLISM; MOUSE MUTANT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NATRIURETIC PEPTIDE, BRAIN;

EID: 84901199526     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3201-4     Document Type: Article

References (38)

1. Cheng S, Fox CS, Larson MG et al (2011) Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol 108:979-984
2. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS (2007) Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115:1345-1353
3. Wang TJ, Larson MG, Levy D et al (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109:594-600
4. Khan AM, Cheng S, Magnusson M et al (2011) Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 96:3242-3249
5. Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB (2010) Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. Endocrinology 151:5218-5225
6. Gutkowska J, Broderick TL, Bogdan D, Wang D, Lavoie JM, Jankowski M (2009) Downregulation of oxytocin and natriuretic peptides in diabetes: possible implications in cardiomyopathy. J Physiol 587:4725-4736
7. Mandavia CH, Aroor AR, Demarco VG, Sowers JR (2013) Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci 92:601-608
8. Oliver PM, Fox JE, Kim R et al (1997) Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 94:14730-14735
9. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS (1998) Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Investig 101:812-818
10. De Vito P, Di Nardo P, Palmery M, Peluso I, Luly P, Baldini PM (2003) Oxidant-induced pHi/Ca2+ changes in rat aortic smooth muscle cells. The role of atrial natriuretic peptide. Mol Cell Biochem 252:353-362
11. Kiemer AK, Vollmar AM (2001) The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 60(Suppl 3):iii68-iii70
12. Stadler K (2012) Oxidative stress in diabetes. Adv Exp Med Biol 771:272-287
13. Pfister R, Sharp S, Luben R et al (2011) Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med 8:e1001112
14. Miyashita K, Itoh H, Tsujimoto H et al (2009) Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58:2880-2892
15. Heinisch BB, Vila G, Resl M et al (2012) B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia 55:1400-1405
16. Bordicchia M, Liu D, Amri EZ et al (2012) Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Investig 122:1022-1036
17. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318-328
18. Potter LR (2011) Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 130:71-82
19. Cheitlin MD, Armstrong WF, Aurigemma GP et al (2003) ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 16:1091-1110
20. Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98:596-605
21. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84:277-359
22. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597-605
23. Meirhaeghe A, Sandhu MS, McCarthy MI et al (2007) Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 16:1343-1350
24. Olsen MH, Hansen TW, Christensen MK et al (2005) N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46:660-666
25. Kim HN, Januzzi JL Jr (2011) Natriuretic peptide testing in heart failure. Circulation 123:2015-2019
26. Thireau J, Karam S, Fauconnier J et al (2012) Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity. Cardiovasc Res 95:59-68
27. O'Connor CM, Starling RC, Hernandez AF et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32-43
28. Lenski M, Kazakov A, Marx N, Bohm M, Laufs U (2011) Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 51:906-918
29. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, de Meester I (2006) Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 52:82-87
30. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Minamino N, Nakao K (2013) Complexity of molecular forms of B-type natriuretic peptide in heart failure. Heart 99:677-679
31. Gower WR Jr, Salhab KF, Foulis WL et al (2000) Regulation of atrial natriuretic peptide gene expression in gastric antrum by fasting. Am J Physiol Regul Integr Comp Physiol 278:R770-R780
32. Engeli S, Birkenfeld AL, Badin PM et al (2012) Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 122:4675-4679
33. Welsh P, McMurray JJ (2012) B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia 55:1240-1243
34. Marfella R, Di Filippo C, Portoghese M et al (2009) Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J Lipid Res 50:2314-2323
35. Ardehali H, Sabbah HN, Burke MA et al (2012) Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail 14:120-129
36. Khairallah RJ, Khairallah M, Gelinas R et al (2008) Cyclic GMP signaling in cardiomyocytes modulates fatty acid trafficking and prevents triglyceride accumulation. J Mol Cell Cardiol 45:230-239
37. Bergandi L, Silvagno F, Russo I et al (2003) Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23:2215-2221
38. Nielsen JM, Kristiansen SB, Norregaard R et al (2009) Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 11:638-647